Tracers / [177Lu]Lu-DOTA-11E10C11
[177Lu]Lu-DOTA-11E10C11
Also written as [Lu-177]Lu-DOTA-11E10C11
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Anti-CDH3 monoclonal antibody conjugated with DOTA chelator (radioimmunoconjugate)
- Target / mechanism
- CDH3 (P-cadherin)-targeting monoclonal antibody 11E10C11 PMID 41570246
- Clinical application
- Targeted radionuclide therapy for triple-negative breast cancer, preclinical PMID 41570246
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | >99% | >99% | CDH3-DOTA China Academy of Engineering Physics, Institute of Nuclear Physics and Chemistry | 41570246 2026 Mol Pharm CDH3-DOTA was mixed with 177LuCl3 ... at a 1:2 molar ratio and incubated at 42 °C in a metal bath for 1 h — TLC analysis demonstrated labeling yields >99% for both radiolabeled conjugates |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-11E10C11, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41570246. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41570246: 'CDH3-DOTA was mixed with 177LuCl3'.